2. Search Result
Search Result
Results for "

IMR32

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103318
    PD173212
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays.
    PD173212
  • HY-100321
    MCHR1 antagonist 2

    		MCHR1 (GPR24) Potassium Channel Metabolic Disease Endocrinology
    MCHR1 antagonist 2 is an antagonist of melanin concentrating hormone receptor 1, with an IC50 of 65 nM; MCHR1 antagonist 2 also inhibits hERG, with an IC50 of 4.0 nM in IMR-32 cells .
    MCHR1 antagonist 2
  • HY-W011762
    VK3-OCH3

    		Others Cancer
    VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity .
    VK3-OCH3
  • HY-133011
    nAChR agonist 1

    		nAChR Neurological Disease
    nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 µM in a Ca 2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .
    nAChR agonist 1
  • HY-111839
    ATRA-hydroxyimino

    CRABP-II ligand 1

    		 Ligands for Target Protein for PROTAC Cancer
    ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells .
    ATRA-hydroxyimino
  • HY-N10890
    Alpinoid D

    		Others Cancer
    Alpinoid D, a diarylheptanoid, can be isolated from the MeOH extract from the rhizomes of Alpinia officinarum Hance. Alpinoid D shows cytotoxic effect against IMR-32 human neuroblastoma cell line .
    Alpinoid D
  • HY-118974
    PD-151307

    		Calcium Channel Neurological Disease Cancer
    PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
    PD-151307
  • HY-P3275
    β-Amyloid (17-40)

    Aβ(17-40)

    		 Amyloid-β Neurological Disease
    β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .
    β-Amyloid (17-40)
  • HY-100310
    N-type calcium channel blocker-1

    		Calcium Channel Neurological Disease
    N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block N-type calcium channels with an IC50 of 0.7 μM in the IMR32 assay.
    N-type calcium channel blocker-1
  • HY-136479
    F0911-7667

    		Others Sirtuin Cancer
    F0911-7667 is a SIRT1 activator that induces autophagic cell death in U87MG and T98G cells by activating the AMPK-mTOR-ULK complex. CWR tripeptide was also identified as a SIRT1 activator that reduced p53 acetylation in IMR32 neuroblastoma cells and protected cells from cell death induced by Aβ fragments .
    F0911-7667
  • HY-124834
    Nrf2 activator-10

    		Keap1-Nrf2 Apoptosis Cancer
    Nrf2 activator-10 (Compound AI-1) is a PI3K-dependent inducer for antioxidant response element (ARE) (EC50 is 2.7 μM) and an activator for Nrf2. Nrf2 activator-10 modifies Keap1, blocks Cul3-Keap1 ubiquitin ligase complex, activates the transcription of Nrf2. Nrf2 activator-10 protects cells from H2O2-induced apoptosis.
    Nrf2 activator-10
  • HY-144878
    VPC-70619
    2 Publications Verification

    		 c-Myc Cancer
    VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration .
    VPC-70619

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: